miR-27a-3p negatively regulates osteogenic differentiation of MC3T3-E1 preosteoblasts by targeting osterix

YUEXIN XU1,3*, DONG LI4*, ZHU ZHU1, LINGYUN LI2, YUCUI JIN2, CHANGYAN MA2 and WEI ZHANG1

1Research Institute of Stomatology, Nanjing Medical University, Stomatological Hospital of Jiangsu Province, Nanjing, Jiangsu 210029; 2Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu 211166; 3Department of Gynecology and Obstetrics, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001; 4Department of Orthopedics, Jiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China

Received September 23, 2019; Accepted April 4, 2020

DOI: 10.3892/mmr.2020.11246

Abstract. Osteoporosis is a complex multifactorial disorder characterized by microarchitectural deterioration, low bone mass, and increased risk of fractures or broken bones. Balanced bone remodeling is tightly regulated by the differentiation, activity and apoptosis of bone-forming osteoblasts and bone-resorbing osteoclasts. MicroRNAs (miRs) are dysregulated in osteoporosis, but whether they control osteogenic differentiation and skeletal biology, or could serve as therapeutic targets remains to be elucidated. The present study identified miR‑27a‑3p as a critical suppressor of osteoblastogenesis. Bioinformatics analysis and luciferase reporter assays demonstrated that miR‑27a‑3p directly targeted and controlled the expression of osterix (Osx), an early response gene essential for bone formation, through its 3'-untranslated region. miR‑27a‑3p functionally inhibited the differentiation of preosteoblasts by decreasing Osx expression, which synergistically contributed to bone formation. miR‑27a‑3p level was significantly decreased during osteogenic differentiation and increased in the serum of patients with osteoporosis. Together, miR‑27a‑3p contributed to diminished osteogenic function during osteogenic differentiation and might thus serve as a therapeutic target and diagnostic biomarker for osteoporosis.

Introduction

Osteoporosis is the most common disorder of bone remodeling in aging humans (1). It is associated with high health costs, and is characterized by an increased propensity to fragility fractures due to progressive loss of bone mass and bone quality, coupled with decreased osteoblast production and function (2,3). In osteoporosis, bone homeostasis is disrupted by hormonal deficiency and aging, leading to increased bone turnover with enhanced bone formation and even greater rates of bone resorption, resulting in net bone loss (4,5). Consequently, safe and effective strategies to stimulate osteoblast formation and activity are in great clinical demand. Anti-osteoporotic agents or food supplements that can stimulate new bone formation and improve trabecular microarchitecture should continue to be investigated for postmenopausal osteoporosis, as emerging therapies hold great promise (6-8).

Micro rnas (mi rnas/mi rs) are a diverse family of endogenous small non-coding RNAs (ncRNAs) that are ~21 nucleotides in length, which post-transcriptionally regulate the stability and translational efficiency of target mrnas (9). mi rnas have been reported to contribute to each step of osteogenesis, starting from embryonic bone development to adult bone tissue maintenance, by regulating the growth, differentiation and functional activity of cells that constitute the bone tissue (10). In addition, substantial quantities of miRNAs are present in body fluids such as serum and plasma as circulating ncRNAs, and have been shown to play roles in cell communication by functioning as hormone-like molecules to influence the behaviors of different cells in a paracrine or endocrine manner (11,12). Due to their high abundance and stability, circulating miRNAs have potential utility as non-invasive, blood-based biomarkers that can provide information on the disease and targeted therapies (13-21).

Icariin, a bioactive plant flavonoid, possesses the ability to stimulate the osteogenic differentiation of bone mesenchymal stem cells, improve osteoporosis in ovariectomized rats and induce bone repair in rabbits (22-27). In a previous study, it was demonstrated that icariin promoted osteogenic differentiation in MC3T3-E1 cells (28). The present study screened the differentially expressed miRNAs in icariin-treated MC3T3-E1 cells and found that miR-27a-3p expression was negatively associated with icariin treatment. Overexpression of miR-27a-3p inhibited osteoblast activity in vitro, as well as decreasing the expression levels of osterix (Osx). Furthermore,
it was verified that Osx, a primary transcription factor required for osteoblast function, was a direct target of miR-27a-3p. Serum miR-27a-3p expression was validated in clinical osteoporosis specimens. Hence, the findings of the present study suggested that miRNAs could be used as a novel diagnostic tool for osteoporosis or serve as novel targets for therapeutic intervention.

Materials and methods

Cell culture. MC3T3-E1 preosteoblasts (obtained from the Cell Center of the Chinese Academy of Medical Sciences) were maintained in Minimum Essential Medium α (α-MEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (PS). 293T cells (American Type Culture Collection) were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS and 1% PS. Cultured cells were incubated at 37°C in a humidified chamber containing 5% CO₂.

Animals. Adult female C57BL/6 mice (weight, 17-20 g; age, 6-8 weeks; n=3) were purchased from the Model Animal Research Center of Nanjing University and maintained under standard animal housing conditions (12-h light/dark cycle and free access to food and water) in a temperature-controlled room (24±1°C) with relative humidity (50±10%) at the animal center of Nanjing Medical University. All procedures involving mice and the corresponding experimental protocols were approved by the Animal Care and Use Committee of Nanjing Medical University (approval no. IACUC-1706005). Following anesthesia by intraperitoneal injection with pentobarbital sodium (100 mg/kg body weight), mice were euthanized by cervical dislocation and the death of mouse was verified 10 min by the following criteria: i) No breathing; ii) no nerve reflexes; iii) no heartbeat and iv) relaxed muscles. Then, the tissues (including the heart, liver, spleen, lung, kidney, bone and brain) were quickly dissected and separately immersed into liquid nitrogen.

RNA oligonucleotides and transfection assay. For transfection, 100 nM inhibitors (5'-GGCGAGCUUUAGCCACUGUGAAG-3'), mimics (5'-UUCAGUGCCUAGUGUCCGC-3') and non-specific control oligonucleotides (5'-UUUCCGGACUGUGCACGUTT-3') of miR-27a-3p were obtained from Invitrogen (Invitrogen, Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions, and RT-qPCR was performed with SYBR Green reagents (Roche Diagnostics) on an ABI 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The expression level of mature miR-27a-3p was determined by stem-loop RT-qPCR. U6 was used for normalization. The following primers sequences were used: miR-27a-3p, RT, 5'-GTCGATACGTGAGGGTCGGCCACTGAACTGTTCTCAGTCGTGGCTTGTCTCAG-3' and reverse, 5'-AAGCCTTTCA CGAATTGCGCT-3'. The PCR amplification conditions were: 95°C for 5 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The following primers sequences were used: Runx-related transcription factor 2 (Runx2), forward, 5'-ATGACACTGCCACCTCTGAC-3' and reverse, 5'-AACCTGCTGGGCTCGAAAG-3'; Osx, forward, 5'-AGCGGACCTTGGGCACAACT-3' and reverse, 5'-GGCGGCTGATGTTGCTTCTC-3'; alkaline phosphatase (ALP), forward, 5'-TGACCTTCTCTCTCCATCCC-3' and reverse, 5'-CTTCTGGGAGTCTCACCCT-3'; osteocalcin (OC), forward, 5'-TGGTTTGAGACGAGCTATCC-3' and reverse, 5'-GAGACAGGGAGGATCAAGT-3'; bone sialoprotein (BSP), forward, 5'-AAGCAGCACCCTGTGATAGG-3' and reverse, 5'-CTTTGGATGTGCTTATCTC-3'; type I collagen (Col1a1), forward, 5'-GCAACAGTGCTTCCACCTACA-3' and reverse, 5'-CAATGTCCAGGGGCACT-3'; β-actin, forward, 5'-GAGGACGTATTCTAGCTTATCT-3' and reverse, 5'-GGCAAGTATGTTTTGTGCA-3'. The relative expression levels were calculated using the 2^(-ΔΔCq) method (29) and normalized to β-actin. For each data point, triplicate reactions were carried out and the experiment was repeated three times to assess statistical significance.

RT-qPCR for Osx expression. Total RNA isolation and cDNA synthesis were conducted as described above. The amplification conditions for PCR were: 95°C for 5 min, followed by 20-30 cycles of denaturation at 95°C for 15 sec, annealing at 56°C for 5 sec and extension at 72°C for 30 sec. The PCR products were analyzed on 8% polyacrylamide gels and visualized using a Tanon 4100 gel imaging analysis system (Tanon). The primers for β-actin and Osx were same as those used for RT-qPCR.

Western blot analysis. Cells were lysed in RIPA buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate (SDS)] plus protease inhibitors (Roche Diagnostics). Protein concentrations were determined using a Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific, Inc.). Total protein (20 µg) samples were boiled for 5 min in 1X loading buffer, incubated on ice, separated via 10% SDS-PAGE and then transferred to PVDF membranes (EMD Millipore) with a semidy transfer apparatus (Bio-Rad Laboratories, Inc.). Non-specific protein interactions were blocked by incubation with 5% fat-free milk in TBS-Tween (TBST) buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.6) for 1 h at room temperature. The membranes were incubated overnight with primary antibody in blocking buffer at 4°C. Unbound
Plasmid construction and luciferase reporter assay. Osx cDNA was inserted into a pRK5 vector (Addgene, Inc.) at the EcoRI and HindIII sites to generate wild-type pRK5-Flag-Osx plasmid. Primer sequences for cloning the Osx CDS sequences were: forward, 5'-CGGAGATTCCAGGTTCCTCTGC TTGA-3' and reverse, 5'-CCCAAGCTTTAGATCCCA GAATTTCG-3'. Fragments of the Osx 3'-untranslated region (3'UTR) containing the miR-27a-3p recognition sequences were inserted behind the luciferase coding sequence at the XbaI site in the pGL3-promoter vector (Promega Corporation). Primer sequences for cloning the Osx 3'UTR sequences were: Wild-type (WT), forward, 5'-CTCTAGAAGCTTGGACCTC CTCAACTT-3' and reverse, 5'-CTCTAGAAGCTTGGACCTC TCAACTT-3'; mutant (MUT), forward, 5'-GGCAGA AAGCTAAGTAAACCTTCTCAAGT-3' and reverse, 5'-ACTTGA AGTTTAGACTTTTCCTGCCC-3'. The PrimeSTAR® Max DNA Polymerase (Takara Biotechnology Co., Ltd.) was used for the PCR, according to the manufacturer's protocol. The amplification conditions were as follows: 98°C for 3 min; followed by 32 cycles of 98°C for 10 sec and 60°C for 90 sec; and a final extension at 72°C for 10 min. For the luciferase assay, 1x10^5 293T cells/well were co-transfected in 24-well plates with the above reporter constructs (0.2 µg) along with phRL-null (0.01 µg; Renilla plasmid for normalization; Promega Corporation) and 100 nM control mimic (miR-C) or miR-27a-3p mimic using Lipofectamine 2000 (Promega corporation) and a GloMax™ Base instrument (Promega Corporation). Densitometric analysis was performed using ImageJ software (version 1.49v; National Institutes of Health). Primary antibodies against Osx (1:4,000; cat. no. ab94744; Abcam) and β-actin (1:1,000; cat. no. sc-47778; Santa Cruz Biotechnology, Inc.) were used.

Bioinformatics prediction and conservative analysis. Potential targets of miR-27a-3p were predicted from three different algorithms: TargetScan Mouse v.6.2 (http://www.targetscan.org), miRanda (http://www.micorna.org/micorna/home.do) and RNA22 (https://cm.jefferson.edu/rna22v1.0-mus_musculus/GetInputs.jsp). TargetScan predicts the biological targets of miRNAs by searching for the presence of conserved 8mer, 7mer and 6mer sites that match the seed region of each miRNA. Potential target miRNAs were selected if they were predicted by ≥2 algorithms. The mature sequences for mmu-miR-27a-3p and hsa-miR-27a-3p were obtained from miRBase (http://www.mirbase.org/) and aligned by ClustalX (http://www.clustal.org).

ALP staining. To induce osteogenic differentiation, cells were cultured in differentiation-inducing medium containing 50 mg/l ascorbic acid, 10 mM β-glycerophosphate and 10 nM dexamethasone for the indicated times with regular medium changes. For ALP staining, after induction for 5-7 days, cells were fixed with 95% ethanol and stained with BCIP/NBT solution according to the manufacturer's protocol (Beyotime Institute of Biotechnology) at room temperature for 2 h. The ALP-positive cells were stained blue/purple. Stained cells were visualized using the Canon IXUS210 camera (Canon, Inc.; magnification, x5). ImageJ version 1.49 software (National Institutes of Health) was used for image analysis and quantification.

Icaritin treatment. Icaritin (94.2% purity) was purchased from the National Institutes for Food and Drug Control. Stock solutions of Icaritin (10 mM) were prepared in DMSO (≥99.7%; Sigma-Aldrich; Merck KGaA) and stored at −20°C. Icaritin treatment was performed as previously described (28). Briefly, MC3T3-E1 cells were cultured in differentiation-inducing medium containing 50 mg/l ascorbic acid, 10 mM β-glycerophosphate and 10 nM dexamethasone, and 5 µM Icaritin for 48 h at 37°C in a humidified chamber containing 5% CO2.

Clinical samples. This study conformed to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Jiangsu Province Hospital of Chinese Medicine. A total of 137 female participants were recruited for this study, including 85 participants with osteoporosis (50-90 years old) and 52 healthy participants (50-90 years old) from the Jiangsu Province Hospital of Chinese Medicine and Northern Jiangsu People's Hospital between February 2014 and April 2019 (Table 1). Each subject underwent a clinical examination, and routine biochemical tests were performed to exclude subjects with systemic and metabolic bone disorders other than osteoporosis. Assessment of the most susceptible sites of osteoporotic fractures, such as the lumbar spine and the head of the femur, by dual X-ray absorptiometry was used as the reference method for measuring total bone mineral density (BMD). The osteoporosis group was defined as BMD T-scores ≤−2.5 at the lumbar. Informed consent was obtained from all participants prior to sample collection. Clinical samples were obtained from the participants, including local health volunteers and patients who were referred to the hospital, who either presented at the bone clinic or the Department of Radiology for a BMD scan. Serum samples were prepared by centrifugation at 2,500 x g for 30 min at room temperature. Aliquots of the supernatants were frozen at −80°C until RNA extraction.

| Age, years | Normal | Osteoporosis |
|------------|--------|--------------|
| 50-59      | 9      | 5            |
| 60-69      | 31     | 32           |
| 70-79      | 8      | 32           |
| 80-90      | 4      | 16           |

Table I. Age distribution of the patients and controls.
**Statistical analyses.** Experimental data were analyzed by Student's t-test or one-way analysis of variance with Bonferroni's correction using GraphPad Prism 6.0 (GraphPad Software, Inc.). All pairs of columns were compared, and the bars denote the mean ± standard deviation from 3 independent experiments. P<0.05 was considered to indicate a statistically significant difference.

**Results**

miR-27a-3p expression is downregulated during osteogenic differentiation. Our previous study demonstrated that icariin treatment significantly elevated the gene expression of osteogenic differentiation of MC3T3-E1 cells (28). The present study first examined the levels of miR-27a-3p during icariin-induced osteogenic differentiation. Results demonstrated that the expression of osteogenic marker genes such as Runx2 and Osx was rapidly increased in MC3T3-E1 cells treated with icariin (5 µM) for 48 h (Fig. 1A), but that of miR-27a-3p was significantly downregulated (Fig. 1B). Notably, miR-27a-3p, encoded by a gene located on mouse chromosome 1, was located at a noncoding region and the precursor sequences displayed the characteristic mirna precursor stem-loop secondary structure according to the miRNA repository miRBase (Fig. 1C). To further evaluate the function of miR-27a-3p, its tissue distribution in normal adult mice was examined by RT-qPCR. The expression of mature miR-27a-3p was detected in all seven types of tissues, including the heart, liver, spleen, lung, kidney, bone and brain. In addition, results demonstrated that miR-27a-3p was preferentially expressed in the liver, bone and brain tissues (Fig. 1D). Analysis by ClustalX demonstrated that miR-27a-3p was highly conserved in both Homo sapiens and Mus musculus (Fig. 1E).

To determine the role of miR-27a-3p in osteoblast lineage commitment, its expression level was detected by culturing MC3T3-E1 preosteoblasts in osteogenic medium for different time periods. As shown in Fig. 1F, miR-27a-3p expression in MC3T3-E1 cells began to decrease over the course of osteogenic differentiation (from days 3 to 12). The expression levels of Runx2 and Osx increased gradually starting from day 3, reaching a maximum on day 7; however, their levels started to decline during the terminal differentiation phase. Together, these findings suggest that miR-27a-3p may function as a miRNA that modulates osteogenic differentiation.

Osx is a direct target of miR-27a-3p. To establish the link between miR-27a-3p and osteoblast function, putative protein targets involved in osteogenic differentiation were screened. Osx, an osteoblast-specific transcription factor, was selected as a target for validation. Single putative miR-27a-3p recognition sites were predicted within the Osx 3'UTR sequences by TargetScan Mouse v.6.2 and RNA22. According to the sequence analysis, Osx contained a 7-nucleotide site within its 3'UTR that matched the seed region of miR-27a-3p (Fig. 2A). Furthermore, tissue distribution analysis demonstrated that the Osx level was highest in the bone (Fig. 2B).

To gain insight into the mechanism via which miR-27a-3p modulates Osx expression, the 3'UTR of the Osx gene containing one miR-27a-3p binding site was fused downstream of a luciferase reporter (Fig. 2C). Results demonstrated that miR-27a-3p mimic significantly inhibited the luciferase reporter activity of the WT Osx 3'UTR compared with miR-C (Fig. 2D). Another luciferase reporter was constructed with an Osx 3'UTR containing mutant sequences of the miR-27a-3p binding site (Fig. 2C). The luciferase reporter activity of the MUT Osx 3'UTR was not suppressed by miR-27a-3p mimic (Fig. 2D). Taken together, introduction of mutations in these sequences abolished the ability of miR-27a-3p to inhibit reporter activity, confirming the selective interaction of miR-27a-3p with miRNAs and indicating that the single recognition element identified in the 3'UTR of the Osx mRNA is sufficient for miR-27a-3p activity. Accordingly, transfection with miR-27a-3p mimic alone decreased the amount of endogenous Osx protein in cultured cells (Fig. 2E), but had no significant effect on Osx mRNA levels (Fig. 2F), suggesting that miR-27a-3p downregulates Osx expression by inhibiting its translation.

miR-27a-3p regulates osteoblast activity in vitro. Due to the role of miR-27a-3p in regulating Osx expression, the physiological effect of miR-27a-3p overexpression on osteogenic differentiation was evaluated in vitro. Results demonstrated that miR-27a-3p levels were substantially upregulated after transfection with miR-27a-3p mimic (Fig. 3A). In addition, the expression of osteoblast marker genes, including ALP, OC, BSP and Col1a1, which are Osx downstream genes, was downregulated in MC3T3-E1 cells transfected with miR-27a-3p mimic compared to that in cells transfected with control mimic (Fig. 3B). Conversely, the expression of these osteoblast marker genes was upregulated in MC3T3-E1 cells transfected with miR-27a-3p inhibitor (Fig. 3C and D). Consistent with the changes in osteoblast marker gene expression, weakened ALP staining was observed in MC3T3-E1 cells transfected with miR-27a-3p mimic compared to that in cells transfected with control mimic (Fig. 3E).

Osx rescues the effect of miR-27a-3p on osteogenic differentiation. Having demonstrated that miR-27a-3p suppresses osteogenic differentiation, it was next assessed whether overexpression of Osx could rescue the effect of miR-27a-3p on osteogenic differentiation in vitro. As shown in Fig. 4A, Osx protein level was enhanced after transfection with Flag-Osx expression plasmid in 293T cells. Of note, when co-transfected with miR-27a-3p mimic and Osx overexpression plasmid, the miR-27a-3p-induced inhibition of osteogenic differentiation was attenuated (Fig. 4B and C). These results suggested that the predominant effect of miR-27a-3p on osteogenic differentiation was mediated via the downregulation of Osx.

Circulating miR-27a-3p level is associated with osteoporosis. Based on BMD, 137 participants were classified into 2 groups: Group A, 52 (female) non-osteoporotic controls; and group B, 85 (female) patients with osteoporosis. Circulating miRNAs from serum samples were tested using RT-qPCR. The results demonstrated that miR-27a-3p levels were significantly elevated in patients with osteoporosis compared with non-osteoporotic controls (Fig. 5). These data suggested that elevated levels of circulating miR-27a-3p in clinical samples may be associated with the development of osteoporosis in patients.
Osteoporosis is one of the major diseases caused by age- or disease-related bone loss (30). A healthy mammalian skeleton is maintained by constant bone remodeling, an active coupling process involving bone-forming osteoblasts and bone-resorbing osteoclasts (5,30). MC3T3-E1 cells, preosteoblasts that mature into preosteocytes in a mineralized matrix, have been stimulated with icariin to induce osteogenic differentiation (28). The present study demonstrated that miR-27a-3p expression was rapidly downregulated during icariin-induced osteogenic differentiation in MC3T3-E1 cells.
A growing body of evidence has revealed that miR-27a-3p acts as a key regulator of bone biology (31-36). Compared to 293T cells, MG63 cells and osteogenic hFOBs cells have been shown to display higher levels of miR-27a due to osteogenesis (34).
In addition, the inhibitory effects of agomiR-27a-3p on the expression of Runx2, Osx, OC and Col1α1 in periodontal ligament stem cells have been demonstrated (35). Overexpression of miR-27a has been shown to weaken ALP and alizarin red staining during osteogenic differentiation of Satb2-induced bone marrow stromal cells (36). Consistent with the inhibitory role of miR-27a-3p in osteogenic differentiation described by these studies, the present study found that the expression of osteogenic marker genes and ALP activity were significantly decreased in miR-27a-3p-overexpressing MC3T3-E1 cells.
Xu et al.: miR-27a-3p REGULATES OSTEOGENIC DIFFERENTIATION VIA OSTERIX

These effects could be reversed by suppression of miR-27a-3p, suggesting that miR-27a-3p is a negative regulator of osteogenic differentiation in MC3T3-E1 cells.

To explore the molecular mechanisms via which miR-27a-3p regulates the osteogenic differentiation of MC3T3-E1 cells, the potential targets of miR-27a-3p were predicted using miRNA target prediction tools. Osx was identified as a potential target of miR-27a-3p. The present study demonstrated that miR-27a-3p directly targeted Osx by binding to its 3'UTR. Osx, a zinc-finger-containing transcription factor, acts downstream of Runx2, and regulates the differentiation and/or function of osteoblasts (37). Our previous study revealed that Osx expression in c2c12 cells is regulated by miR-214, a suppressor of osteogenic differentiation (38). The present study reported that Osx is a direct target of miR-27a-3p and is involved in osteogenic differentiation. Of note, when Osx was overexpressed, osteogenic marker gene expression and ALP activity were restored in miR-27a-3p-overexpressing MC3T3-E1 cells. This indicated that miR-27a-3p inhibited osteogenic differentiation via Osx. Based on these data, it was hypothesized that miR-27a-3p was capable of inhibiting osteogenic differentiation.

Figure 4. Osx rescues the effect of miR-27a-3p on osteogenic differentiation. (A) Western blot analysis of Osx protein level after transfection with Flag-Osx expression plasmid or vector alone in 293T cells. β-actin was used as the internal control. (B) Expression of osteoblast marker genes, as determined by reverse transcription-quantitative PCR following miR-27a-3p-mediated inhibition of osteogenic differentiation in MC3T3-E1 cells with restored expression of Osx. β-actin was used as the internal control. (C) ALP staining analysis after miR-27a-3p-mediated inhibition of osteogenic differentiation in MC3T3-E1 cells with restored Osx expression and quantification of ALP activity. *P<0.05, **P<0.01, ***P<0.001. mir, microRNA; mir-C, control mimic; Osx, osterix; ALP, alkaline phosphatase; OC, osteocalcin; BSP, bone sialoprotein; Col1α1, type 1 collagen.

Figure 5. Circulating miR-27a-3p level is associated with osteoporosis. Circulating miR-27a-3p expression levels in the serum of female patients with osteoporosis (n=85) compared with female non-osteoporotic controls (n=52), as determined by reverse transcription-quantitative PCR. U6 was used as the internal control. ***P<0.001. mir, microRNA.

in vitro.
In postmenopausal osteoporosis, estrogen therapy effectively prevents bone loss (39). Emerging evidence has demonstrated that estrogen exhibits an inhibitory role in osteoclast formation and enhances osteoblast function (40,41). During estrogen-decreased osteoclast differentiation, miR-27a remarkably enhances the inhibitory effect of estrogen (40). In addition, following treatment with antosteoporotic agents, serum miR-27a levels are significantly reduced in postmenopausal women (42). The present study measured the serum levels of miR-27a-3p in 85 samples with osteoporosis and found that the miR-27a-3p levels were significantly higher in osteoporotic patients compared with those in non-osteoporotic controls. These findings implied that miR-27a-3p may serve as a promising marker for the detection of osteoporosis.

Taken together, the results of the present study demonstrated that miR-27a-3p suppressed osteogenic differentiation via downregulating Osx expression. The findings revealed the regulatory role of miR-27a-3p in osteogenic differentiation, and suggested that therapies targeting miR-27a-3p may serve as a promising strategy for the treatment of osteoporosis. The results of the present study provided novel insight into the mechanism by which miRNAs regulate bone physiology.

Acknowledgements

Not applicable.

Funding

This work was supported by grants from the Natural Science Foundation of Jiangsu Province (grant nos. BK20171057, BK20171489 and BK20161323), the National Natural Science Foundation of China (grant nos. 81500823, 81570804 and 81873105).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

YX, DL and ZZ designed the experiments. LL conducted experiments on the clinical samples and provided material support. YX, DL and ZZ performed most of the experiments. YX drafted the manuscript. CM performed the bioinformatics analysis. YJ contributed to the analysis and interpretation of the data. WZ performed the animal experiments and modified the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Informed consent was obtained from all participants. Human studies conformed to the principles of the Declaration of Helsinki and were approved by the Ethics Committee of Jiangsu Province Hospital of Chinese Medicine. All procedures involving mice and the corresponding experimental protocols were approved by the Animal Care and Use Committee of Nanjing Medical University (approval no. IACUC-1706005).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Richards JB, Zheng HF and Spector TD: Genetics of osteoporosis from genome-wide association studies: Advances and challenges. Nat Rev Genet 13: 576-588, 2012.
2. Black DM and Rensen CF: Clinical practice. Postmenopausal osteoporosis. N Engl J Med 374: 254-262, 2016.
3. Kim KM, Park SJ, Jung SH, Kim EJ, Jogeswar G, Ajita J, Rhee Y, Kim CH and Lim SK: MiR-182 is a negative regulator of osteoblast proliferation, differentiation, and skeletogenesis through targeting FoxO1. J Bone Miner Res 27: 1669-1679, 2012.
4. Yu B, Chang J, Liu Y, Li J, Kevork K, Al-Hezaimi K, Graves DT, Park NH and Wang CY: Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-xb. Nat Med 20: 1009-1017, 2014.
5. Long F: Building strong bones: Molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 13: 27-38, 2011.
6. Mulder JE, Kolatkar NS and LeBoff MS: Drug insight: Existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab 2: 670-680, 2006.
7. Guo AJ, Choi RC, Cheung AW, Chen VP, Xu SL, Dong TT, Chen JJ and Tsim KW: Baicalin, a flavone, induces the differentiation of cultured osteoblasts: An action via the Wnt/beta-catenin signaling pathway. J Biol Chem 286: 27882-27893, 2011.
8. Reid IR: Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol 11: 418-428, 2015.
9. Chang TC, Yu D, Lee YS, Wenzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A and Mendell JT: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50, 2008.
10. Lian JB, Stein GS, van Wijnen AJ, Stein JL, Hassan MQ, Gaur T and Zhang Y: MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol 8: 212-227, 2012.
11. Anfossi S, Babayan A, Pantel K and Calin GA: Clinical utility of circulating non-coding RNAs-an update. Nat Rev Clin Oncol 15: 541-563, 2018.
12. Hackl M, Heilmeier U, Weilner S and Grillari J: Circulating microRNAs as novel biomarkers for bone diseases-complex signatures for multifactorial diseases? Mol Cell Endocrinol 432: 83-95, 2016.
13. Zeng HC, Bae Y, Dawson BC, Chen Y, Bertin T, Munivez E, Campeau PM, Tao J, Chen R and Lee BH: MicroRNA miR-23a cluster promotes osteocyte differentiation by regulating TGF-β signalling in osteoblasts. Nat Commun 8: 15002, 2017.
14. Li D, Liu J, Guo B, Liang C, Dang L, Lu C, He X, Cheung HY, Xu L, Lu C, et al: Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun 7: 10872, 2016.
15. Seeliger C, Karpinski K, Haug AT, Vester H, Schmitt A, Bauer JS and van Griensven M: Five freely circulating microRNAs and bone tissue miRNAs are associated with osteoporotic fractures. J Bone Miner Res 29: 1718-1728, 2014.
16. Weilner S, Schraml E, Wieser M, Messner P, Schneider K, Wassermann K, Micutkova L, Fortschegeger K, Maiar AB, Westendorp R, et al: Secreted microvesicular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells. Aging Cell 15: 744-754, 2016.
17. Weilner S, Skalicky S, Salzer B, Keider V, Wagner M, Hildner F, Gabriel C, Dovjak P, Pietschmann P, Grillari-Voglauer R, et al: Differentially circulating microRNAs after recent osteoporotic fractures can influence osteogenic differentiation. Bone 79: 43-51, 2015.
18. Mandourah AY, Ranganath L, Barracho R, Vinjamuri S, Hof RV, Hamill S, Czanner G, Dera AA, Wang D and Barracho DL: Circulating microRNAs as potential diagnostic biomarkers for osteoporosis. Sci Rep 8: 8421, 2018.
19. Chen J, Li K, Pang Q, Yang C, Zhang H, Wu F, Cao H, Liu H, Wan Y, Xia W, et al: Identification of suitable reference gene and biomarkers of serum miRNAs for osteoporosis. Sci Rep 6: 36347, 2016.
20. Ramírez-Salazar EG, Carrillo-Patiño S, Hidalgo-Bravo A, Rivera-Paredes B, Quiterio M, Ramírez-Palacios P, Patiño N, Valdés-Flores M, Salmerón J and Velázquez-Cruz R: Serum miRNAs miR-140-3p and miR-23b-3p as potential biomarkers for osteoporosis and osteoprotective fracture in postmenopausal Mexican-Mestizo women. Gene 679: 19-27, 2018.

21. You L, Pan L, Chen L, Gu W and Chen J: miR-27a is essential for the shift from osteogenic differentiation to adipogenic differentiation of mesenchymal stem cells in postmenopausal osteoporosis. Cell Physiol Biochem 39: 253-265, 2016.

22. Wei Q, He M, Chen M, Chen Z, Yang F, Wang H, Zhang J and He W: Icarin stimulates osteogenic differentiation of rat bone marrow stromal stem cells by increasing TAZ expression. Biomed Pharmacother 91: 581-589, 2017.

23. Wei Q, Zhang J, Hong G, Chen Z, Deng W, He W and Chen MH: Icarin promotes osteogenic differentiation of rat bone marrow stromal cells by activating the ERT-Wnt/β-catenin signaling pathway. Biomed Pharmacother 84: 931-939, 2016.

24. Wu Y, Xia L, Zhou Y, Xu Y and Jiang X: Icarin induces osteogenic differentiation of bone mesenchymal stem cells in a MAPK-dependent manner. Cell Prolif 48: 375-384, 2015.

25. Liu H, Xiong Y, Zhu X, Gao H, Yin S, Wang J, Chen G, Wang C, Xiang L, Wang P, et al: Icarin improves osteoporosis, inhibits the expression of PPARγ, C/EBPα, FABP4, miRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats. Exp Ther Med 13: 1360-1368, 2017.

26. Wang Z, Wang D, Yang D, Zhen W, Zhang J and Peng S: The effect of icariin on bone metabolism and its potential clinical application. Osteoporos Int 29: 535-544, 2018.

27. Zhang Y, Shen L, Mao Z, Wang N, Wang X, Huang X, Hu Y, Shou D and Wen C: Icarin enhances bone repair in rabbits with bone infection during post-infection treatment and prevents inhibition of osteoblasts by vancomycin. Front Physiol 8: 784, 2017.

28. Xu Y, Li L, Tang Y, Yang J, Yin Y and Ma C: Icarin promotes osteogenic differentiation by suppressing Notch signaling. Eur J Pharmacol 865: 172794, 2019.

29. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

30. Kim KM and Lim SK: Role of miRNAs in bone and their potential as therapeutic targets. Curr Opin Pharmacol 16: 133-141, 2014.

31. Ren H, Yu X, Shen G, Zhang Z, Shang Q, Zhao W, Huang J, Yu P, Zhan M, Lyu Y, et al: MiRNA-seq analysis of human vertebrae provides insight into the mechanism underlying GioP. Bone 120: 371-386, 2019.

32. Xu Q, Cui Y, Luan J, Zhou X, Li H and Han J: Exosomes from C2C12 myoblasts enhance osteogenic differentiation of MC3T3-E1 pre-osteoblasts by delivering miR-27a-3p. Biochem Biophys Res Commun 498: 32-37, 2018.

33. Ma Y, Shan Z, Ma J, Wang Q, Chu J, Xu P, Qin A and Fan S: Validation of downregulated microRNAs during osteoclast formation and osteoporosis progression. Mol Med Rep 13: 2273-2280, 2016.

34. Guo D, Li Q, Lv Q, Wei Q, Cao S and Gu J: miR-27a targets sFRP1 in hFOB cells to regulate proliferation, apoptosis and differentiation. PLoS One 9: e91354, 2014.

35. Liu Y, Liu C, Zhang A, Yin S, Wang T, Wang Y, Wang M, Liu Y, Ying Q, Sun J, et al: Down-regulation of long non-coding RNA MEG3 suppresses osteogenic differentiation of periodontal ligament stem cells (PDLSCs) through miR-27a-3p/IGF1 axis in periodontitis. Aging (Albany NY) 11: 5334-5350, 2019.

36. Gong Y, Lu J, Yu X and Yu Y: Expression of Sp7 in Satb2-induced osteogenic differentiation of mouse bone marrow stromal cells is regulated by microRNA-27a. Mol Cell Biochem 417: 7-16, 2016.

37. Zhou X, Zhang Z, Feng JQ, Dusevich VM, Sinha K, Zhang H, Darnay BG and de Crombrugghe B: Multiple functions of osteocalcin are required for bone growth and homeostasis in postnatal mice. Proc Natl Acad Sci USA 107: 12919-12924, 2010.

38. Shi K, Lu J, Zhao Y, Wang L, Li J, Qi B, Li H and Ma C: MicroRNA-214 suppresses osteogenic differentiation of C2C12 myoblast cells by targeting Osterix. Bone 55: 487-494, 2013.

39. Compston JE, McCung MR and Leslie WD: Osteoporosis. Lancet 393: 364-376, 2019.

40. Guo L, Chen K, Yuan J, Huang P, Xu X, Li C, Qian N, Qi J, Shao Z, Deng L, et al: Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARγ and APC. J Cell Physiol 234: 581-594, 2018.

41. Gavali S, Gupta MK, Daswani B, Wani MR, Sirdeshmukh R and Khatkhatay MI: Estrogen enhances human osteoblast survival and function via promotion of autophagy. Biochim Biophys Acta Mol Cell Res 1866: 1498-1507, 2019.

42. Anastasiakidis AD, Makras P, Piklioudou M, Tournis S, Makris K, Bissinas I, Tsavle O, Yvoves JG and Yavropoulou MP: Changes of circulating MicroRNAs in response to treatment with teriparatide or denosumab in postmenopausal osteoporosis. J Clin Endocrinol Metab 103: 1206-1213, 2018.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.